INVEGA INTERVI Trademark

Trademark Overview

On Thursday, February 20, 2020, a trademark application was filed for INVEGA INTERVI with the United States Patent and Trademark Office. The USPTO has given the INVEGA INTERVI trademark a serial number of 88803859. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, August 14, 2023. This trademark is owned by JOHNSON & JOHNSON. The INVEGA INTERVI trademark is filed in the Pharmaceutical Products category with the following description:

Human pharmaceutical preparations for the treatment of central nervous system diseases
invega intervi

General Information

Serial Number88803859
Word MarkINVEGA INTERVI
Filing DateThursday, February 20, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, August 14, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 19, 2020

Trademark Statements

Goods and ServicesHuman pharmaceutical preparations for the treatment of central nervous system diseases

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, February 25, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameJOHNSON & JOHNSON
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew Brunswick, NJ 08933
Party NameJOHNSON & JOHNSON
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew Brunswick, NJ 08933

Trademark Events

Event DateEvent Description
Monday, August 14, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, August 14, 2023ABANDONMENT - NO USE STATEMENT FILED
Wednesday, March 1, 2023ASSIGNED TO EXAMINER
Friday, January 27, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, January 26, 2023SOU EXTENSION 5 GRANTED
Monday, January 9, 2023SOU EXTENSION 5 FILED
Thursday, January 26, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, January 9, 2023SOU TEAS EXTENSION RECEIVED
Friday, October 28, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, October 28, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, October 28, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, July 13, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, July 11, 2022SOU EXTENSION 4 GRANTED
Monday, July 11, 2022SOU EXTENSION 4 FILED
Monday, July 11, 2022SOU TEAS EXTENSION RECEIVED
Friday, January 7, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, January 5, 2022SOU EXTENSION 3 GRANTED
Wednesday, January 5, 2022SOU EXTENSION 3 FILED
Wednesday, January 5, 2022SOU TEAS EXTENSION RECEIVED
Friday, May 14, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, May 12, 2021SOU EXTENSION 2 GRANTED
Wednesday, May 12, 2021SOU EXTENSION 2 FILED
Wednesday, May 12, 2021SOU TEAS EXTENSION RECEIVED
Saturday, December 19, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, December 17, 2020SOU EXTENSION 1 GRANTED
Thursday, December 17, 2020SOU EXTENSION 1 FILED
Thursday, December 17, 2020SOU TEAS EXTENSION RECEIVED
Tuesday, July 14, 2020NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, May 19, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 19, 2020PUBLISHED FOR OPPOSITION
Wednesday, April 29, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, April 6, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, April 6, 2020ASSIGNED TO EXAMINER
Tuesday, February 25, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, February 24, 2020NEW APPLICATION ENTERED

Related Keywords

intervi invega nervous system diseases central treatment pharmaceutical preparations human